Iterum Therapeutics plc - FORM S-1/A - EX-23.1 - CONSENT OF KPMG - May 4, 2018

Attached files

file filename
S-1/A - AMENDMENT #1 TO FORM S-1 - Iterum Therapeutics plcd522368ds1a.htm
EX-10.24 - ADDITIONAL FORM OF WARRANT TO SUBSCRIBE FOR ORDINARY SHARES- LIFE SCIENCES FD II - Iterum Therapeutics plcd522368dex1024.htm
EX-10.23 - ADDITIONAL FORM OF WARRANT TO SUBSCRIBE FOR ORDINARY SHARES- SILICON VALLEY BANK - Iterum Therapeutics plcd522368dex1023.htm
EX-10.22 - WARRANT TO SUBSCRIBE FOR SHARES - LIFE SCIENCES FUND II LLC - Iterum Therapeutics plcd522368dex1022.htm
EX-10.21 - WARRANT TO SUBSCRIBE FOR SHARES - SILICON VALLEY BANK - Iterum Therapeutics plcd522368dex1021.htm
EX-10.20 - INTELLECTUAL PROPERTY SECURITY AGREEMENT - Iterum Therapeutics plcd522368dex1020.htm
EX-10.19 - LOAN AND SECURITY AGREEMENT - Iterum Therapeutics plcd522368dex1019.htm
EX-10.16 - AMENDMENT TO EMPLOYMENT AGREEMENT - JUDITH M. MATTHEWS - Iterum Therapeutics plcd522368dex1016.htm
EX-10.13 - AMENDMENT TO EMPLOYMENT AGREEMENT - COREY N. FISHMAN - Iterum Therapeutics plcd522368dex1013.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors

Iterum Therapeutics plc (formerly Iterum Therapeutics Limited):

We consent to the use of our report dated March 9, 2018, with respect to the consolidated balance sheets of Iterum Therapeutics plc (formerly Iterum Therapeutics Limited) as of December 31, 2017 and 2016, and the related consolidated statements of operations and comprehensive loss, changes in convertible preferred shares and shareholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2017, and the related notes (collectively, the consolidated financial statements), included herein and to the reference to our firm under the heading “Experts” in the prospectus.

/s/ KPMG

Dublin, Ireland

May 4, 2018

Iterum Therapeutics plc Reports